claim: sherlock biosciences receives no emergency use authorization for crispr sars-cov-2 rapid diagnostic
evidence_1: in addition to sherlock, the company is also developing its inspectr platform to create an instrument-free, handheld test  similar to that of an at-home pregnancy test  that utilizes sherlock biosciences synthetic biology platform to provide rapid detection of a genetic match of the sars-cov-2 virus.", "cambridge, mass., may 7, 2020  sherlock biosciences, an engineering biology company dedicated to making diagnostic testing better, faster and more affordable, today announced the company has received emergency use authorization (eua) from the u.s. food and drug administration (fda) for its sherlock crispr sars-cov-2 kit for the detection of the virus that causes covid-19, providing results in approximately one hour."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )